Lenalidomide Grindeks (Lenalidomide)

The drug binds to cereblon, a component of an E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos. This action produces anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant cells in the targeted blood cancers.

The specific dose and schedule are determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and overall health. Only a qualified prescriber can set the appropriate regimen.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended for breastfeeding mothers because it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Lenalidomide belongs to the immunomodulatory class and offers a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, targeted degradation of specific transcription factors, and has demonstrated efficacy in patients who have progressed on or are unsuitable for alternative regimens.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Lenalidomide Grindeks is taken orally as a tablet, usually with or without food, according to the dosing schedule prescribed by the healthcare professional. Patients should follow the exact instructions provided on the prescription label.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe skin reactions like Stevens‑Johnson syndrome, and the possible development of secondary primary malignancies. Prompt medical attention is required if any of these events are suspected.

Lenalidomide is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment unless dose adjustments are made. It should also be avoided in patients taking certain strong CYP3A4 inducers without appropriate monitoring.